Trials / Completed
CompletedNCT06753071
The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder.
The Efficacy of Pyridostigmine Therapy After Transurethral Resection of Prostate in Cases with Underactive Urinary Bladder: Prospective Randomized Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Menoufia University · Academic / Other
- Sex
- Male
- Age
- 45 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The efficacy of pyridostigmine therapy after transurethral resection of prostate in cases with underactive urinary bladder
Detailed description
Underactive bladder is a decrease in detrusor contraction and/or shortening of the contraction time, resulting in an incomplete and/or prolongation of the bladder emptying within the normal time frame. Prolonged bladder outlet obstruction due to prostatic enlargment one of the main causes of bladder hypocontractility. To make a diagnosis, it is necessary to perform a pressure-flow study. Decrease in maximum urine flow rate related to bladder outlet obstruction or poor contractility can be distinguished by pressure-flow study. parasympathomimetics (cholinergic receptor stimulating agents) could be beneficial for patients with underactive bladder. However, no systematic review with meta-analysis addressing potential benefits or adverse effects exists. Pyridostigmine is a medication used to treat myasthenia gravis and underactive bladder as well. Patients with underactive bladder after transurethral resection of prostate may still complain of recurrent attacks of obstructive lower urinary tract symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pyridostigmine oral tablet | Pyridostigmine oral tablet, 60 mg, twice daily, for 3 months |
| DRUG | Placebo | Placebo oral tablet, twice daily, for 3 months |
Timeline
- Start date
- 2024-04-01
- Primary completion
- 2024-07-01
- Completion
- 2025-01-01
- First posted
- 2024-12-31
- Last updated
- 2025-03-26
Locations
1 site across 1 country: Egypt
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06753071. Inclusion in this directory is not an endorsement.